Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
OptiBiotix Health PLC - York-based probiotics developer tackling cardiovascular diseases and lifestyle conditions - Reports higher profit and revenue in 2021 as probiotic business sells more. Pretax profit rises to £6.2 million from £5.7 million in 2020. Revenue from contracts with customers grows 45% to £2.2 million from £1.5 million.
Probiotic business increased sales by 34% to £1.1 million from £800,000 in 2020, OptiBiotix explains. Cites investment increase in Newcastle-based skin health-focused life sciences company SkinBioTherapeutics PLC to £13.7 million in 2021 from £8.9 million in 2020 as as reason for higher profit in 2021.
Looking ahead, says: ‘We have invested substantially in building a stronger professional commercial management team that is well qualified and equipped to lead the business in this next phase of its development, as we look to launch more new products and focus increasingly on selling finished products direct to consumers, while continuing to develop sales of our first-generation ingredients to businesses and working to realise the commercial potential of our development pipeline.’
Current stock price: 20.62 pence, up 0.6% on Tuesday
12-month change: down 61%
Copyright 2022 Alliance News Limited. All Rights Reserved.